AstraZeneca To Pay $520M To Settle Marketing Charges
AstraZeneca has agreed to pay $520 million to settle federal allegations that it improperly marketed its schizophrenia medication Seroquel by pushing favorable research and concealing other research showing the drug's link to diabetes. The company did not admit any wrongdoing. AstraZeneca faces 25,000 civil suits related to the drug, but it will not be subject to criminal charges.
- "For $520 Million, Astra Zeneca Settles Case Over Marketing of a Drug" (Wilson, New York Times, 4/27).